These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 20561148

  • 1. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB.
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [Abstract] [Full Text] [Related]

  • 2. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M, Engström G, Björkbacka H, Hedblad B.
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [Abstract] [Full Text] [Related]

  • 3. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
    Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J.
    Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J.
    Int J Cardiol; 2013 Sep 10; 167(6):2904-11. PubMed ID: 22909410
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ.
    Acta Oncol; 2010 Aug 10; 49(6):805-11. PubMed ID: 20524776
    [Abstract] [Full Text] [Related]

  • 6. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F.
    Liver Int; 2012 Mar 10; 32(3):500-9. PubMed ID: 22098627
    [Abstract] [Full Text] [Related]

  • 7. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
    Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J.
    Clin Microbiol Infect; 2004 May 10; 10(5):409-15. PubMed ID: 15113317
    [Abstract] [Full Text] [Related]

  • 8. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.
    Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J.
    Trop Med Int Health; 2009 Sep 10; 14(9):986-94. PubMed ID: 19725925
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR.
    Am J Cardiol; 2012 Dec 15; 110(12):1756-63. PubMed ID: 22981263
    [Abstract] [Full Text] [Related]

  • 10. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.
    Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J.
    Cancer Epidemiol Biomarkers Prev; 2011 Apr 15; 20(4):609-18. PubMed ID: 21239684
    [Abstract] [Full Text] [Related]

  • 11. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.
    Am J Kidney Dis; 2006 Jan 15; 47(1):139-48. PubMed ID: 16377395
    [Abstract] [Full Text] [Related]

  • 12. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
    Olson FJ, Thurison T, Ryndel M, Høyer-Hansen G, Fagerberg B.
    Clin Biochem; 2010 Jan 15; 43(1-2):124-30. PubMed ID: 19822140
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL.
    Clin Cancer Res; 2002 May 15; 8(5):1132-41. PubMed ID: 12006529
    [Abstract] [Full Text] [Related]

  • 14. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
    Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I.
    Int J Tuberc Lung Dis; 2002 Aug 15; 6(8):686-92. PubMed ID: 12150480
    [Abstract] [Full Text] [Related]

  • 15. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep 15; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 16. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
    Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, Piironen T, Törnblom M.
    J Intern Med; 2011 Mar 15; 269(3):299-305. PubMed ID: 21138491
    [Abstract] [Full Text] [Related]

  • 17. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T.
    J Intern Med; 2013 Jul 15; 274(1):86-100. PubMed ID: 23432143
    [Abstract] [Full Text] [Related]

  • 18. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
    Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 15; 15(5):594-8. PubMed ID: 18753952
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.